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ABSTRACT 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
adjuvant therapy with Omega-3 fatty acids (fish oil) improves joint tenderness in patients with 
Rheumatoid Arthritis. 
 
STUDY DESIGN: Review of 3 double-blind, randomized controlled trials from 2010- 2017.  
 
DATA SOURCES:  Three peer-reviewed journal articles written in English were found using 
PubMed. Articles were selected based on their relevance to the question and whether the 
outcome measured was patient-oriented evidence that matters. 
 
OUTCOME(S) MEASURED: All articles analyzed the effectiveness of adjunctive treatment 
with omega-3 fatty acids on the improvement of joint tenderness in patients with rheumatoid 
arthritis. The overall outcome measured was the number of tender joints before and after 
treatment with omega-3 fatty acids in addition to traditional DMARD therapy.   
 
RESULTS: All three studies found statistically significant improvement in joint tenderness with 
adjunctive treatment with omega-3 fatty acid supplementation. Different concentrations of fish 
oil containing EPA and DHA were administered to the treatment groups and compared to either 
a control or placebo group. Patients complied with the same traditional DMARD therapy in each 
individual study, though the therapies differed between studies.  
 
CONCLUSIONS: This review provides evidence from three separate studies that fish oil 
supplementation decreases the number of tender joints in patients with active RA. Future 
research should focus on increasing sample size and generalizability of research findings, and 
determine the effectiveness of fish oil combined with different DMARD therapies.  
  
KEY WORDS: Fish oils, Fatty acids, Omega-3, and Rheumatoid Arthritis.  
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INTRODUCTION 
Rheumatoid arthritis (RA) is a chronic, progressive, symmetric, inflammatory arthritis 
affecting 1.3 million U.S adults, about 0.6% of the population.1 Middle-aged women are affected 
two times more than men and pose the highest risk. 2 According to a study done in 2009, 
estimated the overall cost of care for RA patients was $39.2 billion.3 In addition, a study in 2008 
found that RA accounted for 36.5 million health care visits.4 Although RA does have genetic 
associations, the cause is still not well understood despite years of research.  
RA is an autoimmune condition causing an immune-mediated attack on joints leading to 
significant inflammation, pain, and decreased joint mobility and function. Most of the 
inflammation is caused by the proliferation of the joint synovium, where there is an 
accumulation of inflammatory immune cells such as neutrophils, CD4 helper T cells, B cells, and 
macrophages. Accumulation of inflammatory cells causes pain and swelling, further leading to 
the production and infiltration of inflammatory mediators such as tumor necrosis factor, 
interleukins, and prostaglandins.5 Multiple joints are affected in a symmetric distribution 
throughout the body, where inflammation and immune-mediated reactions cause erosion of 
cartilage and bone in the joint space.5 
Disease-modifying anti-rheumatic drug (DMARD) therapy remains the mainstay of 
treatment for rheumatoid arthritis, aimed at managing symptoms and decreasing joint 
destruction.6 There are conventional, targeted, and biologic DMARD options which all are 
prescribed with the intent to minimize the inflammatory effects of this condition by targeting 
specific inflammatory molecules; drug examples include, methotrexate, hydroxychloroquine, 
sulfasalazine, leflunomide, corticosteroids, Janus kinase inhibitors, tumor necrosis factor 
antagonists, interleukin-1 receptor antagonists, and interleukin-6 receptor antagonists.7 In severe 
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cases, surgical joint replacement may be needed late in the disease.7 Rheumatoid arthritis 
currently has no ‘cure’ through medical therapy. All of the medications listed above are only 
capable of decreasing disease severity and preventing further damage to joint margins. Each 
DMARD option comes with significant side effects that vary amongst individuals, such as hair 
loss, allergic reactions, gastrointestinal discomfort, mouth sores, hepatotoxicity, and more.7 
Harsh side effects and high risk of individualized adverse drug reactions from DMARD therapy 
have led to multiple clinical trials exploring alternate drug therapies, such as omega-3 fatty acids. 
Omega-3 fatty acids target different inflammatory molecules than traditional DMARD therapy, 
altering the innate inflammatory pathway at a different angle with less adverse side effects.8  
Arachidonic acid (AA) is an omega-6 fatty acid that sits in the phospholipid bilayer of 
cell membranes.8 AA can act as a precursor for many different enzymes involved in the 
inflammatory process such as prostaglandins and leukotrienes. Increased amounts of omega-3 
fatty acids found in fish oil, including eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA), have an inhibitory effect on AA; thus leading to a decreased production of inflammatory 
molecules.8 This mechanism of omega-3 fatty acid proliferation is the focus for determining the 
anti-inflammatory effects that adjunctive supplementation with fish oil has on individuals with 
RA.8 
OBJECTIVE 
The objective of this selective EBM review is to determine whether adjuvant therapy 
with omega-3 fatty acids (fish oil) improves joint tenderness in patients with rheumatoid arthritis. 
METHODS:  
  All three studies were peer-reviewed journal articles written in English, dated from 2010-
2017. Articles were selected using PubMed as a research database. Keywords used in the search 
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included, “Fish Oils," "Fatty acids," "Omega-3," and "Rheumatoid Arthritis." Inclusion criteria 
were as follows: Omega-3 fatty acid supplementation for previously diagnosed Rheumatoid 
Arthritis in an adult, randomized control trials within the past ten years, and measurement of the 
patient-oriented outcome of joint tenderness. Exclusion criteria were also the same for all three 
articles including children less than 18 years old, outcomes that were not patient-oriented, and an 
article that was not a double-blind, randomized control trial. Detailed descriptions of both 
inclusion and exclusion criteria for each individual study is provided in Table 1. The diagnosis of 
RA was based on criteria from the American Rheumatism Association, Association of 
Rheumatology America, and the American College of Rheumatology from the 2010 revision. 
Fish oil supplements, including varying concentrations of EPA and DHA, were used as the 
clinical intervention with a control group or a placebo group as a comparison.  The summary of 
statistics used was both mean change from baseline and p-values.  
OUTCOMES MEASURED: 
 This review focused on determining the mean change from baseline of the number of 
tender joints both before and after the intervention. Data collection in all articles was based on 
the subjective assessment by the patient of their total number of tender joints before and after the 
completion of the supplemental treatment. The Disease Assessment Score (DAS-28) takes into 
account tender joint count, erythrocyte sedimentation rate, and C-reactive protein levels. The 
visual analog scale (VAS) is a continuous scale that ranges from zero, signifying no pain, to 100, 
signifying excruciating pain.5 Veselinovic et al. made assessments at baseline and at three 
months using the DAS-28 and VAS.5 Rajaei et al. made assessments at baseline and every four 
weeks for three months using both DAS-28 and VAS.6 Bahadori et al. made assessments at 
baseline and week one, two, four, 11, and 22 using a trained physician to manually palpate the 
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Table 1. - Demographics and Characteristics of Studies 
Study Type # of 
Pts 
Age 
(yrs) 
Inclusion 
Criteria  
Exclusion  
Criteria  
W/D Interventions 
Bahad
ori B, 
et al. 
20109 
RCT  24 54-62 RA diagnosed 
according to the 
ACRA criteria.  
Stable doses of 
MTX of at least 10 
mg/week and of 
corticosteroids up 
to 10 mg/ day of 
prednisolone were 
required 1 month 
before enrollment. 
11 0.20 g of fish 
oil per kg with 
a specific 
combination 
of EPA, DHA, 
α-linolenic 
acid, 
docosapentaen
oic acid, or a 
placebo. All 
IV for 4 hours 
over 14 days. 
Rajaei 
E, et 
al. 
20156 
RCT 60 20-70  Clinical evaluation 
and diagnosis of 
RA.  
Exclusion criteria:  
Diagnosis > 6 
months, bone 
deformities, 
metabolic and 
gastrointestinal 
diseases, 
medication dose 
fluctuation, use of 
Omega-3 fatty 
acids supplements, 
digestive problems 
& severe infection. 
Exclusion 
Continued: 
AST, ALT, or 
Creatinine levels 
higher than 1.5 
times the 
maximum normal 
limit, total 
bilirubin levels 
more than 1.8 
mg/dL, 
incompletely 
finishing the 12-
week treatment 
course, or absence 
from periodical 
examination 
sessions.  
11 Patients in the 
omega-3 
group 
consumed 2 
omega - 3 
capsules daily 
which 
contained 1.8 
and 2.1 grams 
of EPA and 
DHA.  
 
Veseli
novic 
M, et 
al. 
20175 
RCT 60 Mean 
age 
63.1 
± 9.6  
RA diagnosis 
based on the ACR 
2010 criteria. On 
dosage of NSAIDs 
and/or steroids 
consistently for at 
least 1 month, and 
unchanged during 
the study, while 
the dose of 
DMARDs had to 
be stable for at 
least 2 months. 
Chronic renal, 
liver or heart ds, 
DM, smoking, 
uncontrolled HTN, 
hyperlipidemia, a 
family history of 
cardiovascular ds, 
premature 
menopause, a 
severe folic acid, 
vitamin B6 or B12 
deficiency, and 
other arthritis. 
0 5 g of fish oil 
with 1 g of 
concentrated 
fish oil with 
300 mg of 
DHA, 200 mg 
of EPA, and 
100 mg of 
other n-3 
PUFAs daily 
after meals.  
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 patient’s joints and mark the number of tender joints on a ‘joint mannequin.’9 This review only 
focused on analyzing the mean change from baseline of joint tenderness as a patient-oriented 
evidence that matters (POEM), rather than using values from the DAS-28 and VAS.  
RESULTS: 
Veselinovic et al. carried out a double-blind, randomized controlled trial on 60 female 
patients with a mean age of 63.1 ± 9.6 years.5 Each patient had an established diagnosis of RA as 
determined by the American College of Rheumatology 2010 revised criteria, who were currently 
on the exact same antirheumatic therapy.5 This therapy included up to 10 milligrams per day of 
prednisolone, 15 milligrams per week of oral methotrexate, 10 milligrams per week of folic acid, 
and non-steroidal anti-inflammatory drugs (NSAIDs) as needed.5 Alternate RA drug therapy was 
a component of the exclusion criteria; additional inclusion and exclusion criteria can be found in 
Table 1. Patient demographics were similar in age, body mass index (BMI), and disease duration. 
No patients dropped out of the study. Measurements of the tender joint count were taken at 
baseline with a follow-up assessment at 12 weeks.   
The researchers randomly placed patients in three groups of 20 members.5 The first group 
took 5 grams of fish oil daily after meals.5 The capsules were Omega-3 Cardio® gel capsules, 
each with 1 gram of concentrated fish oil with 300 milligrams of DHA, 200 milligrams of EPA, 
and 100 milligrams of other n-3 polyunsaturated fatty acids (PUFAs).5 The control group 
received the same regimen of antirheumatic drug therapy as the treatment group, without 
administration of Omega-3 Cardio® gel capsules. The third group received a treatment that is not 
applicable to this this review. In order to assess the effect of omega-3 fatty acids as adjunctive 
therapy, joint tenderness was assessed as a subjective measurement by each patient, and the 
researchers determined the mean change from baseline as demonstrated in Table 2. The mean 
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change from baseline in the group that received treatment with omega-3 fatty acids saw 
substantial improvement in joint tenderness. Mean joint tenderness changed from 6.2 to 3.3 in 
the treatment group and only 5.0 to 4.6 in the control group. The p-value was calculated to be 
<0.001, solidifying the statistical significance of these findings. Adverse reactions were only 
found in two patients who experienced gastrointestinal discomfort with mild diarrhea, abdominal 
pain, and dyspepsia. No other side effects were reported.5 
Table 2. – Mean Change From Baseline of Joint Tenderness, Veselinovic et al.5 
Number of tender joints  Omega-3  Control 
Baseline  6.2 ±  2.0 5.0 ±  2.0 
End of study 3.3 ±  1.5 4.6 ±  1.6 
Mean change from baseline -2.4[LARGE] -0.4[SMALL] 
P-value <0.001 
 
Rajaei et al. carried out a double-blind randomized controlled trial on 60 patients, 49 
females and 11 males diagnosed with RA according to the Association of Rheumatology 
America criteria.6 The mean age was 42.4 ± 7 years and 49 patients successfully completed the 
study with only 11 dropouts. Detailed inclusion and exclusion criteria are included in Table 1. 
All subjects were similar in age, sex, drug consumption, and disease duration.6 
The same maintenance antirheumatic therapy was given to each patient that consisted of 
5 milligrams of prednisone twice a day, 200 milligrams of hydroxychloroquine once a day, 0.2 
milligrams per kilogram of body weight of methotrexate per week, and 25 milligrams of 
indomethacin three times a day. Patients were randomly placed in two separate groups, one 
receiving two omega-3 capsules every day containing 1.8 grams of EPA and 2.1 grams of DHA. 
The other group received a placebo pill that contained starch and closely resembled an omega-3 
product created by Anzan Pharmaceutical Company. All patients reported compliance with the 
medications given. Assessments of subjective joint tenderness were made at baseline and every 
four weeks for three months throughout the treatment. The effectiveness of omega-3 treatment 
Fauteux, Fish oil in Rheumatoid Arthritis 7 
	
was determined by 50% improvement seen in 89% of the treatment group (experimental event 
rate, EER= 0.89) and only 13% of the placebo group (control event rate, CER= 0.13) as shown in 
Table 3. Table 3 shows the number needed to treat (NNT) value of 2, meaning for every two 
patients with rheumatoid arthritis, at least 1 patient will have a 50% improvement in joint 
tenderness while taking omega-3 fatty acids, showing a statistically significant improvement (P-
value = <0.05). The Absolute Benefit Increase (ABI) of this treatment was calculated at 0.76 as 
shown in Table 3, demonstrating the increase in improvement of joint tenderness due to the 
intervention. Table 4 demonstrates the mean change from baseline of joint tenderness in both the 
placebo and treatment groups. This is calculated to be a decrease in a tender joint count of 19 in 
the treatment group and only four in the placebo group. Minor adverse reactions from the 
treatment caused two patients to drop out who complained of vomiting and flatulence.6 
Table 3. –ABI, NNT, and statistical significance; Rajaei et al.6 
CER EER Absolute benefit increase 
(ABI) 
Number needed to treat 
(NNT) 
P-value  
0.13 0.89 0.89-0.13 = 0.76 1/0.76 = 1.3= 2  <0.05 
 
Table 4. – Mean change from baseline of joint tenderness, Rajaei et al.6 
Number of tender joints  Omega-3  Placebo 
Baseline  21 24 
End of study 5 20 
Mean change from baseline -19 -4 
P-value <0.05 
 
Bahadori et al. carried out a double-blind, randomized controlled trial including 24 
patients, 23 females and one male, with active RA as diagnosed by the American Rheumatism 
Association criteria.9 The mean age was 58 ± 4 years in the treatment group and 59 ± 2 in the 
placebo group. The initial demographic comparison of the patients was found to be similar in age 
and weight. In order to be included in the study, each patient was required to complete one 
month of 10 milligrams per week of methotrexate and 10 milligrams per day of prednisolone. 
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NSAIDs and paracetamol were allowed as needed and all patients were encouraged to stay on a 
low AA diet throughout the study. Detailed inclusion and exclusion criteria can be found in 
Table 1. Only 13 of the 24 patients successfully completed the study.9 
Researchers randomly placed patients into a treatment group or placebo group and both 
received inpatient intravenous treatments with follow up at one, two, four, 11, and 22 weeks post 
therapy. The treatment group received 0.20 grams of fish oil emulsion per kilogram of body 
weight. Researchers chose Omegaven®, which was a 100 mL containing 6.56 gram of omega-3 
PUFA, comprising 2.82 gram of EPA, 3.09 gram of DHA, 0.20 gram α -linolenic acid, and 0.45 
gram of docosapentaenoic acid. The control group received an equal amount of 0.9% normal 
saline intravenously, which was similar in color to the fish oil emulsion. Both groups were 
treated for four hours every day for 14 consecutive days. A trained physician who determined the 
number of tender joints through manual palpation performed each assessment and documented 
the findings on a joint mannequin.9 
 To determine the effectiveness of omega-3 fatty acid treatment compared to the placebo, 
a mean change from baseline value was calculated as shown in Table 5. The baseline value of 
tender joints was 18 in the treatment group and 17 in the placebo group. Assessments at week 22 
demonstrated that the treatment group had a mean of 15.5 fewer swollen joints and the placebo 
had only nine fewer swollen joints, demonstrating a statistically significant improvement (P-
value = 0.033). Patients in both the omega-3 group and the placebo group experienced adverse  
 
Table 5. - Mean change from baseline of the tender joint count, Bahadori et al.9 
Number of tender joints  Omega-3  Placebo 
Baseline  18 17 
End of study-week 22 2.5 8 
Mean change from baseline -15.5 -9 
P-value 0.033 
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reactions in a very similar distribution, making it less likely that the adverse reactions were 
caused by the fish oil treatment. Symptoms reported included local infusion reaction, feeling 
uncomfortable, nausea, diarrhea, headache, and depression.9 
DISCUSSION: 
 Rheumatoid arthritis is a common inflammatory arthritis that causes significant pain and 
discomfort with decreased joint mobility. This review highlights the effectiveness of adjunctive 
omega-3 fatty acid supplementation on the decrease in the number of tender joints in patients 
with active RA receiving traditional DMARD therapy.  Both Rajaei et al6 and Veselinovic et al5 
used oral capsules of omega-3 fatty acids with varying amounts of EPA and DHA, while 
Bahadori et al9 used intravenous treatment. The effectiveness of omega-3 fatty acids was shown 
to significantly improve the number of tender joints in each patient population. Baseline 
DMARD therapy was relatively consistent across studies including methotrexate or 
hydroxychloroquine, folic acid, and a corticosteroid agent. Although these treatments are not 
identical, the important point to focus on is the time in which the subjective joint tenderness was 
recorded. Baseline measurements were made while patients were already taking DMARD 
therapy. The end measurement was taken only after omega-3 fatty acids were added to their 
treatment regimen. Although each study delivered treatment in different ways and had varying 
baseline DMARD therapy, all three study results implied the significant positive impact that 
adjunctive treatment with omega-3 fatty acids has specifically on joint tenderness.  
A limitation of this review was the low number of articles selected for analysis on this 
topic; future reviews would benefit from more than five randomized controlled trials. The 
limitations found in all three studies included a low sample size and predominantly female 
populations. The route of administration and varying amounts of EPA, DHA, and other 
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ingredients in the omega-3 supplement were also inconsistent across all three studies. The 
subjectivity of joint tenderness as the POEM leads to increased variability in all three studies. 
Veselinovic et al discussed the lack of a blinded placebo control group as a limitation, which was 
chosen due to the ingredients in most placebo pills having a possible impact on study outcome.5 
Bahadori et al had a large number of dropouts combined with the smallest sample size out of all 
three studies, making it difficult to relate the research findings to the general population. Lastly, 
a large limitation that is difficult to control in this research is the varying impact that traditional 
DMARD therapy has on each individual patient. Rather than fish oil supplementation causing 
improved joint tenderness alone, it’s likely a combination of both DMARD therapy and fish oil 
improves the symptoms of joint tenderness.   
 Omega-3 fatty acids are sold as fish oil tablets and contain varying concentrations of EPA 
and DHA. This affordable product is readily available in most drug stores in the United States 
and is sold as an over-the-counter medication not covered by insurance. Few omega-3 fatty acid 
supplements are sold as prescription products; however, Lovaza® is a combination of EPA and 
DHA ethyl esters, is one example that may be covered by insurance.10  
   
CONCLUSION: 
 All three studies provided statistically significant evidence suggesting the positive impact 
that omega-3 fatty acid supplementation has on joint tenderness on patients with active 
rheumatoid arthritis. The number of tender joints decreased substantially in each treatment group 
that received fish oil as adjunctive therapy to traditional DMARD therapy when compared to the 
control groups. Future research should aim at broadening the sample populations including more 
research on males with RA and increasing the sample size.  Ideally, one large study with several 
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hundred adult RA patients of both genders diagnosed based on the same criteria, treated with the 
same baseline DMARD therapy, and receiving the same concentrations of EPA and DHA in the 
fish oil supplementation would provide more valid results. Controlling for extraneous factors that 
impact the results of this intervention will be difficult but could provide beneficial evidence to 
improve both joint function and tenderness in patients with RA.  
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